A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function
Clinical trial NCT04482270 · COMPLETED
Trial details
- NCT number
- NCT04482270
- Sponsor
- Astellas Pharma Global Development, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-02
- Primary completion
- 2021-03-22
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.